Xencor, Inc. (XNCR)
After hours:
| Previous close | 23.63 |
| Open | 24.26 |
| Bid | 23.97 x 100 |
| Ask | 24.13 x 100 |
| Day's range | 24.01 - 25.09 |
| 52-week range | 16.49 - 28.96 |
| Volume | |
| Avg. volume | 733,606 |
| Market cap | 1.486B |
| Beta (5Y monthly) | 0.76 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.08 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 36.58 |
GuruFocus.comInsider Sale at Xencor Inc (XNCR): EVP, Chief Development Officer Nancy Valente Sells Shares
On May 2, 2024, Nancy Valente, the Executive Vice President, Chief Development Officer of Xencor Inc (NASDAQ:XNCR), sold 4,745 shares of the company.
ZacksXencor (XNCR) Moves 14.3% Higher: Will This Strength Last?
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Business WireXencor Appoints Bart Cornelissen as Chief Financial Officer
PASADENA, Calif., April 09, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Mr. Cornelissen has more than 20 years of experience in corporate financial planning, analysis and transaction support. Before joining Xencor, he was most recently vice president, corporate finance at
